Movement Alert|PHARMARON Falls 3.06% in Regular Trading, Sector-Wide CXO Weakness Weighs on Shares

Market Focus11-11

On November 11, PHARMARON fell 3.06% in Regular Trading, trading at HK$29.14 with turnover of HK$31.13 million.

The clearest catalyst cited for the move was broad weakness across the Life Sciences Tools & Services group rather than a new company-specific negative development.

Recent market updates indicated that PHARMARON had disclosed generally supportive items, including JPMorgan's off-exchange purchase of 771,700 H shares at about HK$26.01 per share, lifting its long position ratio to 17.19%, Morgan Stanley's increase in shares subject to rehypothecation or disposal rights that raised its long position ratio to 6.05%, and a US$10 million commitment by its wholly owned UK subsidiary to HJ Double Helix Fund L.P. Even so, peer pressure dominated on November 11, with WUXI APPTEC down 4.89%, WUXI BIO down 4.31%, GENSCRIPT B-1K down 6.15%, WUXI XDC down 4.24%, and INSILICO down 2.05%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment